Faruqi and Faruqui, LLP Logo
Share this page

TG Therapeutics, Inc. (TGTX)

NASDAQ:TGTX

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In TG Therapeutics, Inc. To Contact The Firm Before Lead Plaintiff Deadline

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in TG Therapeutics, Inc.  (“TG” or the “Company”) (NASDAQ:TGTX) of the March 7, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased TG common stock between September 15, 2014 and October 12, 2016 (the “Class Period”).  The case, Lyon v. TG Therapeutics, Inc. et al, No. 1:17-cv-00112 was filed on January 6, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by misrepresenting and/or omitting material information concerning the GENUINE Phase III trial for its proprietary combination of drug therapies TG-1101 and TGR-1202, assuring investors it was a “best-in-class treatment” that would be “successful” and “offer patients a novel chemo-free treatment option.”

Specifically, on October 13, 2016, TG announced it filed an “amended protocol for its GENUINE Phase 3 trial,” which entirely abandoned Part II of the Phase III GENUINE study, thereby annulling the Special Protocol Assessment with the U.S. Food and Drug Administration (“FDA”). Accordingly, the study’s sole primary endpoint was reduced to only overall response rate, and the target enrollment was reduced to only 120 patients. As a result, TG stated it could be another two years to reach 330 patients, the number needed to have sufficient powering to show a progression-free survival benefit.

On this news, TG’s share price fell from $8.25 per share on October 12, 2016 to a closing price of $6.01 on October 17, 2016—a $2.24 or a 27.15% drop.

Take Action

If you invested in TG stock or options between September 15, 2014 and October 12, 2016 and would like to discuss your legal rights, please fill out the form below. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding TG’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    TG Therapeutics, Inc. (TGTX)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 01/06/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.